Metacrine raises $65M to kick off NASH clinical testing by Conor Hale Wednesday, June 6, 2018 Metacrine raised $65 million to launch phase 1 testing of its FXR agonist in NASH and gastrointestinal diseases later this month.
Enyo raises $47M to bring hep B, NASH drug to phase 2 by Conor Hale Monday, June 4, 2018 Enyo Pharma raised nearly $47 million to launch the first two phase 2 clinical trials of EYP001, its lead candidate in hep B and NASH, before 2019.
Charles River’s target identification tech helps Enyo Pharma by Angus Liu Wednesday, November 29, 2017 Enyo Pharma has successfully identified potential targets of its preclinical molecule series EYP002 with Charles River's technology.
